Natco Pharma Ltd.

In accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, NATCO Pharma has informed that, Tummala Venkata Rao, Vice President – Production of the Company has superannuated today with effect from the closure of business hours on 31st March, 2025. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024 are enclosed.

The above information is a part of company’s filings submitted to BSE.